Larvol Delta - Biosyngen39s-Cell-Therapy-BRG01-Granted-Orphan-Drug-Designation-by-the-US-FDA-for-Treatment-of-Nasopharyngeal-Cancer

BRG01 - Biosyngen

https://en.prnasia.com/releases/apac/biosyngen-s-cell-therapy-brg01-granted-orphan-drug-designation-by-the-u-s-fda-for-treatment-of-nasopharyngeal-cancer-406845.shtml

Jun 6, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next